H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into two registrational severe uncontrolled asthma studies with a “product angle that could matter commercially”. The firm added that it believes the company’s setup is better than the stock implies.

Generate Biomedicines, Inc. (NASDAQ:GENB) also received a rating update from Cantor Fitzgerald on March 24. The firm initiated coverage of the stock with an Overweight rating, telling investors in a research note that the company is developing GB-0895, which is a long-acting anti-TSLP antibody for asthma and COPD discovered through its computational protein engineering platform. It is viewed as a largely de-risked, high-reward asset with blockbuster potential and a 65% probability of success in asthma.

Generate Biomedicines, Inc. (NASDAQ:GENB) is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.